FIELD: medicine; ophthalmology.
SUBSTANCE: invention relates to medicine, namely to ophthalmology. An ophthalmological examination is performed using optical coherence tomography. In this case, the thickness of the retina from the retinal pigment epithelium to the inner boundary membrane, the structure of the choroid in the Cross Line protocol, performed through the center of the fovea in the horizontal and vertical meridians, is evaluated. Measurements are carried out at five points from the outer border of the pigment epithelium to the inner border of the sclera in the projection of the fovea, parafovea and perifovea with a step of 500 microns from the nasal and temporal sides. A study is carried out using optical coherence tomography in the angiography mode and perfusion in the superficial, deep vascular plexuses, architectonics and choroidal thickness is assessed on 3D scans and En Face. The area of myopic chorioretinal neovascularization (mChNV) is measured, the concentration of hormones is examined by taking blood from days 5 to 9 of the menstrual cycle: cortisol, follicle-stimulating hormone, prolactin, estradiol, progesterone. Lipidogram is examined with the determination of lipoprotein (a), and when determining the axial length of the eyeball of 24.0-28.0 mm, the thickness of the choroid> 50 microns, the type of subretinal neovascular membrane "sea fun", lipoprotein (a) 14-30 mg/dl, prolactin hormones > 800 mME/ml, FSH > 11.3 mME, cortisol > 1,000 nmol/l, progesterone < 1.5 nmol/l, estradiol < 50 nmol/l, a favorable course of mChNV is predicted and 1-3 intravitreal injections of anti-VEGF drug are prescribed. When determining the axial length of the eyeball > 28 mm, the thickness of the choroid < 50 microns, the type of subretinal neovascular membrane "tree-in-bud", lipoprotein (a) 31-50 mg/dl, prolactin hormones > 1,000 mME/ml, FSH > 11.3 mME, cortisol > 2 times the norm of gmol/l, progesterone < 1 nmol/l, estradiol < 50 nmol/l, an unfavorable course mChNV is predicted and more than 3 intravitreal injections of the anti-VEGF drug are prescribed.
EFFECT: method makes it possible to increase the reliability of predicting the effectiveness of prescribing hormonal anti-VEGF therapy in patients with mChNV by constructing a prognostic model that includes an ophthalmological assessment and a study of the somatic status.
1 cl, 4 dwg, 2 ex, 2 tbl
